Integrated network pharmacology, molecular docking, and experimental validation to reveal the potential mechanism of Ginsenoside Rg1 on chronic obstructive pulmonary disease
Xinpeng Li, Dandan Xiang, Lingling Hu, Lingdan Lin, Guoqiang Wang, Jing Xu · 2026
Read Integrated network pharmacology, molecular docking, and experimental validation to reveal the potential mechanism of Ginsenoside Rg1 on chronic obstructive pulmonary disease by Xinpeng Li, Dandan Xiang, Lingling Hu, Lingdan Lin, Guoqiang Wang, Jing Xu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13550585.txt.
Description
Xinpeng Li, with five colleagues, published a 2026 study of a ginseng compound in lung disease. The disease, called COPD, causes long-term airway swelling and harm. The compound, ginsenoside Rg1, fights swelling and cell stress in lab work. The team asked how it might help, using computer tools and cell tests.
Computer screening found 105 targets shared by the compound and the disease. Two signaling routes stood out, both centered on a protein called EGFR. In airway cells stressed by smoke extract and a bacterial toxin, the compound cut swelling and mucus output. Protein tests showed lower activity on both routes. The results point to a clear path for more tests.
Catalog record
| CREATOR | Xinpeng Li, Dandan Xiang, Lingling Hu, Lingdan Lin, Guoqiang Wang, Jing Xu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36064 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |